BAUSCH HEALTH COS INC (BHC) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BHC - CA0717341071 - Common Stock
BHC Key Statistics, Chart & Performance
The current stock price of BHC is 6.35 USD. In the past month the price decreased by -3.93%. In the past year, price decreased by -24.13%.
BHC Latest News, Press Relases and Analysis
BHC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About BHC
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Company Info
BAUSCH HEALTH COS INC
2150 St. Elzear Blvd. West
Laval QUEBEC H7L 4A8 CA
CEO: Joseph C. Papa
Employees: 20700
Phone: 18003611448
BAUSCH HEALTH COS INC / BHC FAQ
What does BAUSCH HEALTH COS INC do?
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
What is the current price of BHC stock?
The current stock price of BHC is 6.35 USD. The price increased by 1.6% in the last trading session.
What is the dividend status of BAUSCH HEALTH COS INC?
BHC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BHC stock?
BHC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is BAUSCH HEALTH COS INC (BHC) expected to grow?
The Revenue of BAUSCH HEALTH COS INC (BHC) is expected to grow by 6.13% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for BHC stock?
BAUSCH HEALTH COS INC (BHC) currently has 20700 employees.
Who owns BAUSCH HEALTH COS INC?
You can find the ownership structure of BAUSCH HEALTH COS INC (BHC) on the Ownership tab.
BHC Technical Analysis
BHC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BHC. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BHC Financial Highlights
Over the last trailing twelve months BHC reported a non-GAAP Earnings per Share(EPS) of 3.82. The EPS increased by 1.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.61% | ||
| ROA | 1.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BHC Forecast & Estimates
9 analysts have analysed BHC and the average price target is 7.26 USD. This implies a price increase of 14.37% is expected in the next year compared to the current price of 6.35.
For the next year, analysts expect an EPS growth of 5.69% and a revenue growth 6.13% for BHC